Cellsorba™ EX

ASAHI LEUKOCYTAPHERESIS (LCAP) COLUMN

Leukocyte removal for ulcerative colitis and Crohn’s disease

- For treatment of inflammatory bowel disease (IBD)
- Removal of leukocytes, which are implicated in inflammation (granulocyte, monocyte, lymphocyte)
- Easy handling - direct haemoperfusion -
- Gamma Sterilized / ETO Free

ASAHI KASEI MEDICAL CO., LTD.
A Pioneer in Blood Purification
Features & Benefits

Features:
1. INNOVATIVE - LCAP therapy using the leukocyte removal filter, Cellosorba, removes leukocytes, which are implicated in inflammation (e.g., granulocyte, monocyte, lymphocyte). This principle can be used to influence the clinical status of patients in relation to their inflammatory state.
2. EASY - Simple, extracorporeal procedure, which requires approximately one hour per session.

Benefits:
CLINICAL EFFICACY - Remission and improvement were observed in 74% of active ulcerative colitis patients. (Matsumoto. et al. Ther Apher Dial. 12:484-90, 2008)

Structure
Whole blood flows into the cylindrical non-woven fabric. The non-woven fabric removes leukocytes through filtration and adhesion.

Circuit Diagram

Specifications
<table>
<thead>
<tr>
<th>Materials</th>
<th>Non-woven fabric made of polyethylene terephthalate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column volume</td>
<td>170 mL</td>
</tr>
<tr>
<td>Column dimensions</td>
<td>200mm[L] - 45mm[D]</td>
</tr>
<tr>
<td>Sterilization</td>
<td>Gamma-Ray</td>
</tr>
</tbody>
</table>

AsahiKASEI

Manufacturer:
ASAHI KASEI MEDICAL CO., LTD,
1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006 Japan
TEL: +81-3-6699-3771 FAX: +81-3-6699-3773
URL: http://www.asahikasei-medical.com

Represented in Europe by:
ASAHI KASEI MEDICAL EUROPE GmbH
Hermesstrasse 1, 60529 Frankfurt am Main Germany
TEL: +49 (0) 69 66 37 15 00 FAX: +49 (0) 69 66 51 93

Copyright © 2018 Asahi Kasei Medical Co., Ltd, Printed in Japan No, 2018.7-2340